Skip to main content

Table 2 Laboratory test results of pulmonary tuberculosis patients notified in Shanghai, China, in the first half of each of 2017 and 2018

From: Effect of the Xpert MTB/RIF on the detection of pulmonary tuberculosis cases and rifampicin resistance in Shanghai, China

Characteristics

Total

n (%)

(n = 6047)

PTB patients of 2017

n (%)

(n = 2938)

PTB patients of 2018

n (%)

(n = 3109)

p-value

Sputum smear

   

< 0.001

 Negative

3784 (62.6)

1812 (61.7)

1972 (63.4)

 

 Positive

1802 (29.8)

850 (28.9)

952 (30.6)

 

 Not available

461 (7.6)

276 (9.4)

185 (6.0)

 

Sputum culture

   

< 0.001

 Negative

2123 (35.1)

1000 (34.0)

1123 (36.1)

 

 Positive

2786 (46.1)

1285 (43.7)

1501 (48.3)

 

 Not available

1138 (18.8)

653 (22.3)

485 (15.6)

 

Xpert result for MTB

   

 Negative

782 (12.9)

782 (25.2)

 

 Positive

909 (15.0)

909 (29.2)

 

 Not available

4356 (72.0)

2938 (100)

1418 (45.6)

 

Xpert result for RIF resistancea

   

 Susceptible

840 (92.4)

840 (92.4)

 

 Resistant

69 (7.6)

69 (7.6)

 

Culture-based DST result for RIF resistanceb

   

0.784

 Susceptible

2188 (78.5)

1008 (78.4)

1180 (78.6)

 

 Resistant

118 (4.2)

58 (4.5)

60 (4.0)

 

 Not available

480 (17.2)

219 (17.0)

261 (17.4)

 
  1. PTB Pulmonary tuberculosis
  2. Xpert Xpert MTB/RIF
  3. MTB Mycobacteria of tuberculosis
  4. RIF Rifampicin
  5. DST Drug susceptibility test
  6. acalculated among Xpert MTB positive patients
  7. bcalculated among culture positive patients